Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Public ClinicalTrials.gov record NCT03704467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study identification
- NCT ID
- NCT03704467
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Interventions
- M6620 Drug
- Avelumab Drug
- Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2019
- Primary completion
- Nov 5, 2019
- Completion
- Nov 5, 2019
- Last update posted
- Nov 12, 2020
2019
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Marin Cancer Care, Inc. | Greenbrae | California | 94904 | — |
| The Stamford Hospital | Stamford | Connecticut | 06904 | — |
| Covenant Health Care | Saginaw | Michigan | 48604 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065-6007 | — |
| Mount Sinai - PRIME | New York | New York | 11041 | — |
| Peggy & Charles Stephenson Oklahoma Cancer Ctr | Oklahoma City | Oklahoma | 73104 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75251 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03704467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03704467 live on ClinicalTrials.gov.